In the disease-burdened provinces of northeastern Iran, where two species of a skin-ravaging parasite have long confounded clinicians, researchers have devised a molecular test that reads the thermal fingerprint of Leishmania DNA to distinguish one species from another within a single day. The method — qPCR-HRM — closes a diagnostic gap that once forced physicians to treat patients on guesswork while cultures grew and sequencing results traveled slowly back from distant laboratories. Though the study is preliminary, it points toward a future in which the right treatment can follow the right di
New qPCR test rapidly distinguishes Leishmania species causing cutaneous leishmaniasis
Cutaneous leishmaniasis affects patients in northeastern Iran, requiring improved diagnostic methods for appropriate treatment.
A difference of roughly 0.86 degrees that proved consistent and reproducible
Mark
Why does it matter which Leishmania species someone has? Aren't they both treated the same way?
Mimi
Not entirely. The species can differ in how aggressive they are, how they respond to certain drugs, and what the long-term scarring looks like. Knowing which one you're dealing with helps a doctor choose the right treatment faster and manage expectations with the patient.
Mark
And the old way of figuring out which species it was—that took weeks?
Mimi
Yes. You'd have to grow the parasite in culture, which is slow, or send the sample away for genetic sequencing. In a place like northeastern Iran where leishmaniasis is endemic, waiting weeks means patients are suffering longer than they need to.
Mark
So this new test cuts that down to a day?
Mimi
One working day, ideally. It works by heating the DNA and watching when it unwinds. Each species unwinds at a slightly different temperature—less than a degree apart, but consistent enough to tell them apart reliably.
Mark
That seems like a small difference. How confident are they that it actually works?
Mimi
In their test, it worked perfectly. Every sample they identified with the new method matched what genetic sequencing confirmed. But they're being honest about the limits—they only found one species in their samples, so they haven't actually proven the test can catch the other species in real patients yet.
Mark
So it's promising but not ready for hospitals?
Mimi
Exactly. It's ready for the next phase of testing. They need to run it on hundreds more samples, from different regions, where both species are actually present. That's the work ahead.
El Pulso
- Patients in northeastern Iran with cutaneous leishmaniasis have long faced delayed diagnoses because distinguishing L. major from L. tropica required slow culture growth or weeks-long genetic sequencing.
- The two species demand different treatment strategies, meaning misidentification — or the absence of identification — carries real consequences for patient outcomes.
- Researchers developed a qPCR-HRM assay that exploits a consistent 0.86°C difference in DNA melting temperatures to separate the two species reliably within a single working day using widely available lab equipment.
- Testing on 60 suspected cases yielded 13 confirmed Leishmania infections, all identified as L. major — results that matched gold-standard DNA sequencing with perfect agreement.
- Genetic analysis of the 13 isolates revealed nine sequence types and seven haplotypes, hinting at significant parasite diversity with potential implications for transmission and treatment resistance.
- The assay's promise is real but unfinished: validation on larger, geographically diverse samples representing both species must come before it can enter routine clinical use.
In the disease-burdened provinces of northeastern Iran, where two species of a skin-ravaging parasite have long confounded clinicians, researchers have devised a molecular test that reads the thermal fingerprint of Leishmania DNA to distinguish one species from another within a single day. The method — qPCR-HRM — closes a diagnostic gap that once forced physicians to treat patients on guesswork while cultures grew and sequencing results traveled slowly back from distant laboratories. Though the study is preliminary, it points toward a future in which the right treatment can follow the right diagnosis before the disease deepens its hold.
In the northeastern provinces of Iran, cutaneous leishmaniasis has long pressed against the limits of local diagnostic capacity. The two species most responsible — Leishmania major and Leishmania tropica — can call for different treatments, yet telling them apart has historically meant waiting days or weeks for cultures or sequencing results. In the meantime, clinicians were left to guess.
Researchers from North Khorasan and Razavi Khorasan provinces set out to close that gap. They developed a test called qPCR-HRM, which targets a specific region of the parasite's genetic material and measures the precise temperature at which its DNA strands unwind. Each species produces a distinct thermal signature: L. major separates at roughly 84.13°C, L. tropica at 83.27°C — a difference of about 0.86°C that proved consistent and reproducible across experiments.
The team applied the assay to samples from 60 patients suspected of infection. Thirteen tested positive, all identified as L. major. When those same samples were confirmed by DNA sequencing, the results matched without exception. Genetic analysis of the isolates also revealed nine distinct sequence types and seven haplotypes, suggesting the regional parasite population carries considerable hidden diversity.
The test's chief advantage is speed: results arrive within a single working day, using equipment already present in most diagnostic laboratories. But the researchers are measured in their conclusions. Because all positive cases in this study were L. major, the assay's ability to correctly flag L. tropica in real patient samples remains untested. Larger, more geographically varied studies — capturing both species — will be necessary before qPCR-HRM can move from research tool to clinical routine. The foundation has been laid; the validation work lies ahead.
In the northeastern provinces of Iran, where cutaneous leishmaniasis has long been a public health concern, researchers have developed a new molecular test that can identify which species of Leishmania parasite is causing infection in a matter of hours rather than days. The test, called quantitative real-time PCR coupled with high-resolution melting analysis, or qPCR-HRM, works by targeting a specific region of the parasite's genetic material and measuring how the DNA unwinds at different temperatures—a process that produces a distinct fingerprint for each species.
The distinction matters because Leishmania major and Leishmania tropica, the two species most commonly found in Iran, can require different treatment approaches and carry different epidemiological implications. Until now, confirming which species a patient carried meant waiting for cultures to grow or sending samples for genetic sequencing, a process that could take weeks. Clinicians treating patients in the meantime often had to make educated guesses about which parasite they were dealing with.
Researchers in North Khorasan and Razavi Khorasan provinces tested their new assay on clinical samples from 60 patients suspected of having cutaneous leishmaniasis. They extracted DNA from cultured parasites and ran them through the qPCR-HRM test, then compared the results against both conventional PCR methods and DNA sequencing. The new test reliably separated the two species based on melting temperature—the point at which the DNA strands separate. Leishmania major melted at approximately 84.13 degrees Celsius, while Leishmania tropica melted at 83.27 degrees, a difference of roughly 0.86 degrees that proved consistent and reproducible.
Of the 60 samples examined, 13 tested positive for Leishmania infection. All 13 were identified as Leishmania major by the qPCR-HRM assay, and when those same samples were sent for genetic sequencing as a confirmation step, the results matched perfectly. The researchers also analyzed the genetic diversity within those 13 Leishmania major isolates, finding nine distinct sequence types and seven different haplotypes—a finding that suggests the parasite population in the region has considerable genetic variation, which could have implications for how the disease spreads and responds to treatment.
The speed of the test is its most practical advantage. Where conventional methods require days or weeks of waiting, qPCR-HRM can produce results in a single working day, allowing clinicians to adjust treatment protocols quickly if needed. The test is also relatively inexpensive and requires only standard laboratory equipment that many diagnostic centers already have on hand.
However, the researchers are careful not to overstate what they have accomplished. Their study was preliminary, conducted on a limited number of samples from a specific geographic region. All the positive cases they found were Leishmania major; they had no opportunity to test the assay's ability to identify Leishmania tropica in actual patient samples. Before this test can be adopted as a routine diagnostic tool in hospitals and clinics, they say, it will need to be validated on a much larger scale, with samples representing both species and drawn from diverse patient populations across different regions. The promise is clear, but the work of turning promise into clinical practice is still ahead.
Citas Notables
Further validation using larger numbers of direct clinical specimens representing both species is required before routine diagnostic application— Study researchers
Quieres la nota completa?
Lee el original en Nature ↗
Culture & Arts